Tongli Haiyuan Biotechnology
Daxing
About Tongli Haiyuan Biotechnology
Tongli Haiyuan Biotechnology focuses on the R&D and production of GMP-grade core raw material reagents for upstream cell and gene therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $13.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2023)
- Website: seafrom.cn
- Phone: 010-6864-0843
Industries & Categories
Biopharma, Biotechnology, Medical
Canonical: https://fsome.com/organization/tongli-haiyuan-biotechnology-131941 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.